Motley Fool? A HAS BEEN. They have not had anything right in 12 years. Now they call CLDN a buy and the "fools" run it up for a short time, only to fail. Cramer and Motley---stay away!!!!
PRTA has not shown safety and efficacy yet--still need phase 2 and 3 results, a long way to go, to catch up to ACAD even if ACAD does have problems
ACAD already completed phase 3 test on its Parkinson drug with FDA approval. What is the difference? or just the hype for PRTA?
So why the run up on PRTA? drug by ACAD already approved by FDA for use
It appears to me they are in similar markets with similar devices/chips. So why does AMBA sell at a premium? A lot of hype about their chips in GoPro. Who has the better chips? Who has the better technology?
With all of the SSYS patents for 3D, what is HPQ action to get into 3D? They are running our of time
book value of $24/share. Enterprise value of $3bil, market cap only $1bil---very undervalued